ClinicalTrials.gg
CompletedNCT02186080Updated Apr 21, 2016

Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia

An interventional study of Gemigliptin and Placebo in Type 2 Diabetes Mellitus, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-21.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Enrollment
18th of 18
10 · median 130
Started
2014
with 4 others
No phase
Only one
of the 18
Registered
8th of 18
by date
Lead sponsor
2 of 18
Seoul National University Hospital

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 18th largest by enrollment, is one of 5 that started in 2014, is the only one with no phase, and was the 8th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This is an exploratory study on the metabolic endotoxemia associated with type 2 diabetes. The investigators will measure systemic endotoxin level and lipid level after ingestion of high fat diet to evaluate the effect of gemigliptin, a DPP-4 inhibitor, on metabolic endotoxemia and lipemia induced by high fat diet.

Read the detailed description

Study subjects will be allocated to either gemigliptin or placebo. After 4 weeks of treatment and 2 weeks of wash out period, all subjects will be switched to the opposite arm.

The subjects will be tested oral fat tolerance test and adipose tissue needle biopsy(only for the subjects who agreed to participate donate adipose tissue) at 3 time points: the start of 1st treatment, end of 1st treatment and end of 2nd treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • diabetes mellitus
  • metabolic endotoxemia
  • gemigliptin
  • DPP-4 inhibitor
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 20 to 75
  • At least 6 months from the diagnosis of type 2 diabetes
  • Current diabetes treatment: life style modification and/or metformin and/or sulfornylurea
  • No change of the diabetes treatment (drug number and dossage) in recent 3 months
  • 6.5% to 10%

Exclusion criteria

Exclusion Criteria:

  • Recent cardiovascular event in 6 months
  • Concurrent use of statin or fibrate or ezetimibe
  • Renal failure, chronic liver disease
  • Pregnancy or lactation
  • Use of other DPP-4 inhibitor or GLP-1 analogue in recent 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Gemigliptin

    Gemigliptin 50mg qd added to subjects current diabetes treatment

    Drug: Gemigliptin

  • Placebo comparator
    Placebo

    Placebo (identical in appearance to gemigliptin)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Difference between baseline and peak serum LPS

    The increment of serum LPS after ingestion of high fat diet

    Time frame: serum LPS before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet

Secondary outcomes

  1. Fasting serum LPS level

    Compare fasting LPS level between treatment group

    Time frame: After 10 hrs of fasting

  2. Incremental AUC of serum LPS during oral fat tolerance test

    Calculated incremental AUC of serum LPS

    Time frame: serum LPS before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet

  3. Difference between baseline and peak serum triglyceride level

    The increment of serum TG after ingestion of high fat diet

    Time frame: serum TG before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet

  4. Incremental AUC of serum triglyceride level during oral fat tolerance test

    Calculated incremental AUC of serum TG

    Time frame: serum TG before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet

  5. Difference between baseline and peak serum apolipoprotein-B48

    The increment of serum apolipoprotein-B48 after ingestion of high fat diet

    Time frame: serum apolipoprotein-B48 before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet

  6. Incremental AUC of serum apolipoprotein-B48 during oral fat tolerance test

    Calculated incremental AUC of serum apolipoprotein-B48

    Time frame: serum apolipoprotein-B48 before high fat diet and 15 min, 30 min, 1 hr, 2 hr, 3 hr, 4 hr after high fat diet

  7. Serum level of inflammatory markers (CRP, TNF-alpha, IL-6)

    Compare serum level of inflammatory markers between treatment groups

    Time frame: After 10 hr of fasting

  8. mRNA expression level of inflammatory markers in the adipose tissue

    Compare mRNA expression level of inflammatory markers

    Time frame: After high fat diet ingestion

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 10, 2014
Start
Jul 2014
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Apr 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02186080
Collaborators
LG Life Sciences
Responsible party
Sponsor
First posted
Jul 10, 2014
Start date
Jul 2014
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Apr 21, 2016

Study contacts

Young Min Cho, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion